Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: A phase i study

Clinical Drug Investigation

Volumn 33, Issue 6, 2013, Pages 419-427

  Stass, Heino ^a   Nagelschmitz, Johannes ^a   Willmann, Stefan ^b   Delesen, Heinz ^a   Gupta, Abhishek ^c   Baumann, Sybille ^d  

^a BAYER PHARMA AG   (Germany)

^b BAYER AG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CRS Clinical Research Services Mannheim GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BRONCHUS; COMPUTER MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DRY POWDER INHALER; DYSGEUSIA; ELECTROCARDIOGRAM; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LUNG FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRACHEA;

ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; CROSS-OVER STUDIES; DRY POWDER INHALERS; HALF-LIFE; HUMANS; LUNG; MALE; SINGLE-BLIND METHOD; TISSUE DISTRIBUTION;

EID: 84878695314     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0082-0     Document Type: Article

References (43)

1. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-8.
2. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101(8):1633-8.
3. Moss RB. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis. 1995;21:839-51.
4. Valderrey AD, Pozuelo MJ, Jimenez PA, et al. Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis. 2010;68(1):20-7.
5. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3):158-61.
6. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10(8):1754-60.
7. Kulich M, Rosenfeld M, Goss CH, et al. Improved survival among young patients with cystic fibrosis. J Pediatr. 2003;142(6):631-6.
8. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30.
9. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491-9.
10. Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis. 2007;1(1):61-76.
11. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50(10):1313-21.
12. Ciofu O, Fussing V, Bagge N, et al. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother. 2001;48(3):391-6.
13. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121(1):55-63.
14. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.
15. Piddock LJ, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother. 1998;42(11):2956-60.
16. Alder J, Wilson R, Welte T, et al. Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. Amsterdam: European Respiratory Society; 2011.
17. Endermann R, Labischinski H, Ladel C, et al. Treatment of bacterial diseases of the respiratory organs. US Patent 2004/0254194 A1. 2004.
18. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17(2):168-74.
19. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360-6.
20. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175-82.
21. Pharmacopoeia Online. 601 Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers (online). http://www.uspbpep.com/usp31/v31261/ usp31nf26s1-c601.asp. Accessed 16 Sept 2011.
22. European Pharmacopoeia 6.2. https://www.pheur.org/store/images/majbdd/ 200710301703120.6-2%20E%20Index.pdf. Accessed 16 Sept 2011.
23. Gupta A, Tarara T, Miller D, et al. A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections (abstract no. R6156). American Association of Pharmaceutical Scientists Annual Meeting, Washington; 23-27 Oct 2011.
24. Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of 6 years and older. J Aerosol Med. 2006;19(4):456-65.
25. Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401-31.
26. Willmann S, Lipworth BJ, Sevestre M, et al. PK-Sim: a physiologically based pharmacokinetic 'whole-body' model. Biosilico. 2003;1(4):121-4.
27. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2012. doi: 10.1183/09031936.00071312.
28. Gonzalez MA, Uribe F, Moisen SD, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984;26(5):741-4.
29. Stass H, Baumann-Noss S, Delesen H, et al. Pharmacokinetics of inhaled ciprofloxacin powder (abstract no. P103). In: Proceedings of 31st European Cystic Fibrosis Conference, Prague; 11-14 June 2008.
30. Smith MJ, White LO, Bowyer H, et al. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1986;30(4):614-6.
31. Plaisance KI, Drusano GL, Forrest A, et al. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1987;31(6):956-8.
32. Drusano GL, Standiford HC, Plaisance K, et al. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986;30(3):444-6.
33. Forrest A, Weir M, Plaisance KI, et al. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother. 1988;32(10):1537-40.
34. Wingender W, Graefe KH, Gau W, et al. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984;3(4):355-9.
35. Bondesson E, Bengtsson T, Nilsson LE, et al. Site of deposition and absorption of an inhaled hydrophilic solute. Br J Clin Pharmacol. 2007;63(6):722-31.
36. Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42(4):307-13.
37. Westerman EM, de Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm. 2007;335(1-2):41-5.
38. Westerman EM, de Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007;6(4):284-92.
39. Crowther Labiris NR, Holbrook AM, Chrystyn H, et al. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1711-6.
40. Goldman JM, Bayston SM, O'Connor S, et al. Inhaled micronised gentamicin powder: a new delivery system. Thorax. 1990;45(12):939-40.
41. Le Brun PP, de Boer AH, Mannes GP, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm. 2002;54(1):25-32.
42. EUCAST. European Committee on Antimicrobial Susceptibility Testing. MIC distribution (online). http://www.eucast.org. Accessed 1 Jan 2011.
43. Weers J, Clark A, Challoner P. High dose inhaled powder delivery: challenges and techniques. In: Respiratory Drug Delivery IX: River Grove: Amy Davis Biggs 2004; pp 281-8.